Navigation Links
ResMed Patent Infringement Case Against BMC Advances: International Trade Commission Agrees to Investigate
Date:8/21/2013

SAN DIEGO, Aug. 21, 2013 /PRNewswire/ -- The International Trade Commission has agreed to investigate Chinese medical device manufacturer BMC Medical Co., Ltd., and its distributors, Florida-based 3B Medical Inc. and 3B Products, L.L.C.. The Investigation was initiated at the request of ResMed (NYSE: RMD), a global innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions. ResMed also filed suit in federal court against BMC in May, asserting patent infringement by:

  • The RESmart CPAP and RESmart Auto CPAP devices, and
  • The Willow nasal pillows patient interface and the iVolve nasal mask.
  • (Logo: http://photos.prnewswire.com/prnh/20100203/RESMEDLOGO)

    ResMed pursued a similar legal action earlier this year against Taiwanese manufacturer APEX Medical Corp. asserting patent infringement that resulted in APEX consenting to an order barring infringing products from the U.S. market.

    "We're encouraged by the ITC's action to investigate this case against BMC," said ResMed Global General Counsel and Chief Administrative Officer David Pendarvis. "For more than two decades, ResMed has generated significant advances in innovative products for sleep-disordered breathing therapy We invest over $100 million in research and development each year to fuel these advances and other companies should not be allowed to infringe ResMed's intellectual property by using our technology."

    About ResMed:
    ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.Contacts:For News MediaFor the Finance and Investor CommunityGretchen Griswold

    Constance BienfaitDirector, Global Corporate Communications

    Director, Investor RelationsO: 858-836-6789

    O: 858-836-5971news@resmed.com

    constance.bienfait@resmed.com


    '/>"/>
    SOURCE ResMed Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
    2. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
    3. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
    4. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
    5. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
    6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
    7. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
    8. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
    9. ResMed Takes Action to Enforce Patents
    10. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
    11. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/18/2017)... Iowa , Jan. 18, 2017   ... that subsidiary Caretta Therapeutics plans, in the second ... Venodol, a topical roll-on intended to provide relief ... opioid and steroidal analgesics. It was developed under ... to commercialize products derived from snake venom. ...
    (Date:1/18/2017)...  Dermata Therapeutics, LLC, a biotechnology company developing ... of dermatological diseases, announces dosing the first patient ... 2 acne rosacea study. DMT210 is a topical ... in the skin responsible for the inflammation and ... This clinical trial, DMT210-003, is a 12-week, Phase ...
    (Date:1/18/2017)... Jan. 17, 2017  With an annual growth ranging from 6% to 10%, ... SEA (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the ... CPhI SEA 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program ... ...
    Breaking Medicine Technology:
    (Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment ... they have achieved certification to ISO 13485. This certification is another way they are ... date products and services that they need. , The ISO 13485 Certification is a ...
    (Date:1/18/2017)... NJ (PRWEB) , ... January 18, 2017 , ... ... care communications company, launched a new website for its Center for Biosimilars, announced ... will include the latest developments in the field of biosimilars through thought leader ...
    (Date:1/18/2017)... ... January 18, 2017 , ... ... gum disease to enamel erosion, and those dental problems can increase the risk ... Health, many pregnant women are failing to get the dental care they need. ...
    (Date:1/17/2017)... ... January 17, 2017 , ... Anesthesia Progress ... dentists to choose the best drug option for each patient. Dentists have several general ... better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan wanted ...
    (Date:1/17/2017)... ... , ... For breast cancer clinicians and researchers who were unable to attend ... intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual ... on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO ...
    Breaking Medicine News(10 mins):